Skip to main content

Table 1 Baseline Patient Demographic and Clinical Characteristics

From: Fast-track multidisciplinary treatment versus conventional treatment for colorectal cancer: a multicenter, open-label randomized controlled study

Characteristic

Groups

P value

Group1 (FTMDT)

P value

1(FTMDT)

2(Conventional)

Subgroup 1a

Subgroup 1b

Age, years (M, IQR)

60 (53–66.5)

61 (54–69)

0.3415

61 (52–66)

60 (54–67)

0.7559

Gender, F/M (F%)

62/110 (36)

67/103 (39)

0.5210

30/57 (34)

32/53 (38)

0.6660

BMI, M (IQR)

22.6 (20.8–24.6)

22.67 (20.6–24.84)

0.9457

22.1 (21.2–24.8)

23.02 (20.65–24.55)

0.7215

ASA grade, n (%)

  

0.3920

  

0.6340

 I

156 (91)

148 (87)

 

78 (90)

78 (92)

 

 II

16 (19)

21 (12)

 

9 (10)

7 (8)

 

 III

0 (0)

1 (1)

 

0 (0)

0 (0)

 

CEA, ng/mL, M (IQR)

6.7 (3.8–15.2)

5.6 (2.9–12.1)

0.3007

6.1 (3.1–12.9)

7.0 (4.8–20.8)

0.2561

CA199, U/mL, M, (IQR)

28.1 (7.0–77.8)

29.8 (7.0–51.0)

0.6492

16.8 (6.1–57.0)

28.3 (10.5–103.2)

0.1482

Site of Cancer, n (%)

  

0.5110

  

0.8810

 Ascending colon

31 (18)

35 (21)

 

18 (21)

13 (15)

 

 Transverse colon

13 (8)

12 (7)

 

6 (7)

7 (8)

 

 Descending colon

20 (12)

24 (14)

 

11 (13)

13 (15)

 

 Sigmoid colon

50 (29)

38 (22)

 

24 (28)

26 (31)

 

 Rectum

54 (33)

65 (36)

 

28 (32)

26 (31)

 

Maximum tumor diameter, cm, M (IQR)

4 (3.5–5)

4 (3–5)

0.3358

4 (3–5)

5 (4–6)

0.0084

Pathologic type, n (%)

     

0.1400

 Adenocarcinoma

148 (86)

146 (86)

0.6260

73 (84)

75 (88)

 

 Mucinous adenocarcinoma

9 (5)

13 (8)

 

6 (6.90)

3 (4)

 

 Other

3 (2)

2 (1)

 

3 (3)

0 (0)

 

 Missing

12 (7)

9 (5)

 

5 (6)

7(8)

 

Differentiation, n (%)

  

0.3840

  

0.8480

 Well

20 (12)

20 (12)

 

11 (13)

9 (11)

 

 Moderate

104 (60)

115 (68)

 

51 (59)

53 (62)

 

 Poor

34 (20)

25 (15)

 

18 (21)

16 (19)

 

 Missing

14 (8)

10 (5)

 

7 (8)

7 (8)

 

Lymph nodes, M (IQR)

15 (11–20)

15 (12–18)

0.7319

14 (9–19)

16 (11–21)

0.3270

pT stage, n (%)

  

0.8070

  

0.0210

 1

9 (5)

9 (5)

 

7 (8)

2 (2)

 

 2

27 (16)

22 (13)

 

11 (13)

16 (19)

 

 3

91 (53)

96 (56)

 

53 (61)

38 (45)

 

 4

33 (19)

28 (16)

 

11 (13)

22 (26)

 

 Missing

12 (7)

15 (10)

 

5 (6)

7 (8)

 

pN stage, n (%)

  

0.5360

  

0.5620

 0

97 (56)

88 (52)

 

48 (55)

49 (58)

 

 1

39 (23)

46 (27)

 

23 (26)

16 (19)

 

 2

25 (15)

21 (12)

 

12 (14)

13 (15)

 

 Missing

11 (6)

15 (9)

 

4 (5)

7 (8)

 

pTNM stage (n, %)

  

0.7110

  

0.6720

 I

27 (16)

23 (14)

 

13 (15)

14 (16)

 

 II

66 (38)

63 (37)

 

32 (37)

34 (40)

 

 III

66 (38)

69 (41)

 

36 (41)

30 (35)

 

 IV

1 (1)

0 (0)

 

1 (1)

0 (0)

 

 Missing

12 (7)

15 (8)

 

5 (6)

7 (9)

 
  1. FTMDT Fast-track multi-discipline treatment, M (IQR) Median (interquartile range), F/M Female/male, F% Percent of females in subgroup, BMI Body mass index, ASA American Society of Anesthesiologists, n number, CEA Carcinoembryonic antigen, CA199 Carbohydrate antigen 19–9, pT pathological T stage, pN pathological N stage, pTNM pathological 7th edition TNM stage
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us